Alaunos Therapeutics Inc. (NASDAQ: TCRT) reported that its lead obesity candidate, ALN1003, produced significant weight‑loss and metabolic improvements in two diet‑induced obesity mouse studies conducted on March 2 2026. The studies showed a mean percent change in body weight loss of up to 12.9 % and a reduction in liver weight of up to 55 % compared with controls, indicating strong anti‑obesity activity.
The pre‑clinical data also revealed favorable liver enzyme profiles, with lower alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase levels, and improved blood glucose and cholesterol levels. No severe adverse effects were reported in the animal models, underscoring the safety profile of the oral, non‑hormonal formulation.
Despite the encouraging efficacy data, Alaunos remains a pre‑clinical‑stage company with limited financial resources. As of September 30 2025, the company had approximately $1.9 million in cash, providing a runway that extends into the second quarter of 2026. The new data may support future financing efforts, and a recent proposal for a $7 million private placement could lead to a change of control if completed.
CEO Holger Weis said, "These early non‑GLP data support ALN1003's potential as a non‑hormonal treatment to achieve meaningful body weight loss with favorable body composition changes and select liver‑related findings. We are focused on additional preclinical studies, optimizing formulations and refining manufacturing processes as we advance toward studies to enable an Investigational New Drug (IND) application. ALN1003 has the potential to offer a new option for patients seeking alternatives to hormone‑based obesity drugs."
The company plans to use the findings to guide further pre‑clinical work, optimize formulations, and prepare for IND‑enabling studies. Successful progression to IND status will be a critical step toward clinical development and will likely be a key factor in attracting the additional capital needed to sustain the program.
While the pre‑clinical milestone is a positive development, Alaunos remains in the early stages of development and its future depends on securing additional funding to move ALN1003 into human trials. The company’s financial position and the potential for a change of control underscore the importance of the upcoming financing round for the continued advancement of its obesity program.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.